Triple

T10292323
Position Surface form Disambiguated ID Type / Status
Subject ENSEMBLE trial E241392 entity
Predicate developerOfInvestigationalProduct P40576 FINISHED
Object Ad26.COV2.S E241393 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ad26.COV2.S | Statement: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Ad26.COV2.S
Context triple: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
  • A. Ad26.COV2.S chosen
    Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
  • B. human adenovirus serotype 26 (Ad26)
    Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
  • C. SARS-CoV-2
    SARS-CoV-2 is the novel coronavirus responsible for the global outbreak of the respiratory disease COVID-19.
  • D. BNT162b2
    BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
  • E. Human mastadenovirus D
    Human mastadenovirus D is a species of human adenoviruses that includes multiple serotypes, some of which are used as viral vectors in vaccine development and gene therapy.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: developerOfInvestigationalProduct
Context triple: [ENSEMBLE trial, developerOfInvestigationalProduct, Ad26.COV2.S]
  • A. coPrincipalInvestigator
    Indicates that an entity serves jointly with another as a principal investigator on the same research project or grant.
  • B. chiefScientist
    Indicates that one entity serves as the primary or lead scientist for another entity, typically holding top scientific authority or responsibility.
  • C. developerOfWork
    Indicates that one entity is the creator or producer responsible for making or developing a particular work.
  • D. developmentLedBy chosen
    Indicates that the development of something is directed, managed, or overseen by a particular agent or entity.
  • E. overseesDevelopmentOf
    Indicates that one entity has responsibility for supervising, managing, or directing the development process of another entity.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d381aaafc08190af475ef58dc16aba completed April 6, 2026, 9:49 a.m.
NER Named-entity recognition batch_69d4d2d35f048190a215493acdf1f718 completed April 7, 2026, 9:48 a.m.
NED1 Entity disambiguation (via context triple) batch_69d7500fdd1c81909395469afb346f8b completed April 9, 2026, 7:06 a.m.
PD Predicate disambiguation batch_69d4d1f35e548190be3b4d92d65d2d20 completed April 7, 2026, 9:44 a.m.
Created at: April 6, 2026, 11:42 a.m.